FLT3 and acute myeloid leukemia: In AML, different types of TKIs, such as FMS-like tyrosine kinase 3 (FLT3) inhibitors, have shown efficacy in FLT3-mutated AML and have improved the outcome of some types of AML, including patients with FLT3 mutations [6-8].